Response of a patient with bullous pemphigoid (BP) after 6 omalizumab injections as monotherapy. A, Involvement of the back of a steroid-refractory patient with BP before omalizumab treatment. B, Four months after beginning omalizumab as monotherapy, the inflammatory plaques have largely resolved, leaving postinflammatory hyperpigmentation and a small number of erosions and mild, transient erythema. The patient cleared completely after a second cycle of omalizumab treatment.